Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

Back to Myeloproliferative Neoplasm

Myeloproliferative Neoplasm — NIH Grants & Funding

Active and recent NIH-funded research on Myeloproliferative Neoplasm. Data from NIH RePORTER, last 36 months.

MONDO:0020076

NIH-funded research on Myeloproliferative Neoplasm

active grants

institutions

researchers

new in last 12 mo.

$51.2M in NIH funding over the last 36 months. Data from NIH RePORTER.

I'm looking for:

Or filter by research focus

Only show active grants

Basic Science(27)

Basic ScienceR35Active

Identifying the mechanisms of leukemia progression

Crispino, John·ST. JUDE CHILDREN'S RESEARCH HOSPITAL·MEMPHIS, TN

$1,077,000 (FY2025)

Myeloproliferative Neoplasm — NIH Grants & Funding

Basic Science(27)

Identifying the mechanisms of leukemia progression

Targeting cancer neoantigens in patients with myeloid malignancies

Divergent Functions of ERK Substrate Binding Domains in Pathogenesis of Myeloproliferative Neoplasms

Dysregulated NFkB Pathway Signaling In Myeloproliferative Neoplasms

Molecular Basis for Progression of Myeloproliferative Neoplasms Induced by JAK2V617F

The Role of miR-142 in the Transformation of Clonal Hematopoietic Disorders into AML

Extrinsic regulation of primitive, myeloid-biased hematopoietic stem cells by Semaphorin 4a

The Pathophysiology of Type 1 Versus Type 2 Mutant Calreticulin-Drivenmyeloproliferative Neoplasms

Molecular mechanisms of splicing dependency in cohesin-mutant myelodysplasia

Calreticulin-mediated protein folding in health and disease

Translational(11)

Targeting Immune Escape in CML/MPN Transformation

Mechanisms of treatment-free remission in a mouse model of chronic myeloid leukemia

Thrombopoietin Targeting in Myeloproliferative Neoplasms

Targeting cancer stem cells in JAK2V617F induced neoplasm

Targeting altered phosphatase-dependent signaling to overcome the inefficacy of targeted therapy in myeloproliferative neoplasms

Targeting dysregulated transcriptome as therapy for post-myeloproliferative neoplasm (MPN) sAML

Oncogenic tyrosine kinases inhibitors abrogate DNA repair and sensitive leukemias to PARP inhibitors

Targeting of IL-1 Signaling in Myelofibrosis

Target the Dusp1 in Jak2 dependent myeloproliferative neoplasm (MPN) for curative treatment

Elucidating Mechanisms of Therapy-Resistance to Interferon-alfa in Myeloproliferative Neoplasm Stem Cells - Diversity Supplement

Clinical(3)

Myeloproliferative Neoplasms-Research Consortium

Understanding and targeting bone marrow microenvironment in myelofibrosis

Investigation of the impact of pegylated Interferon on clonal trajectory and inflammatory cytokine production in MPN patients

Epi / Nat. History(1)

Selective pressures from inherited variation impacting myeloproliferative neoplasm initiation

Biomarker / Dx(3)

Developing small molecule inhibitors of Pleckstrin-2 to treat thrombosis

Development of quantitative bone marrow magnetic resonance imaging biomarkers to assess efficacy of novel molecularly targeted agents for myelofibrosis

MPN-inducing mutations as biomarkers of synthetic lethality

Other(1)

Tracing the lineage histories and differentiation trajectories of individual cancer cells in myeloproliferative neoplasms